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Abstract
A retrospective cohort study was conducted including 3,688 patients age 60 years or older without 
dementia enrolled in a depression screening study in primary care clinics. Information on 
antidepressant use and incident dementia during follow-up was retrieved from electronic medical 
records. Cox’s proportional hazard models were used to compare the risk for incident dementia 
among five participant groups: SSRI only, non-SSRI only (Non-SSRI), mixed group of SSRI and 
non-SSRI, not on antidepressants but depressed, and not on antidepressants and not depressed. 
SSRI and Non-SSRI users had significantly higher dementia risk than the non-depressed non-users 
(HR=1.83, p=0.0025 for SSRI users and HR=1.50, p=0.004 for non-SSRI users). In addition, 
SSRIs users had significantly higher dementia risk than non-users with severe depression 
(HR=2.26, p=0.0005).
Future research is needed to confirm our results in other populations and to explore potential 
mechanism underlying the observed association.
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1. Introduction
Depression is common among elderly patients with prevalence rates around 10–15% for 
those living in the community1–3. Antidepressants are one of the most commonly prescribed 
drugs in the United States. In the 1990s, selective serotonin re-uptake inhibitors (SSRI) 
became the first line of drug treatment for depression, replacing tricyclic antidepressants 
(TCA)4. Antidepressants have been hypothesized to have neuroprotective effects5,6 such as 
improved memory and cognition7. In addition, it has been suggested that treatment with 
SSRIs may improve cognitive function in patients with Alzheimer's dementia8, although this 
is not consistent across studies. However, little is known about the long-term outcomes of 
antidepressant use in the elderly population with intact cognitive functions. Older adults are 
often under-represented in clinical trials of antidepressants and the short duration of such 
trials are often limited to a few weeks or months9,10. There have been few long-term studies 
to date investigating the association between antidepressant use and the risk of dementia.
Prior reports have pointed to potentially differential and complex relationships between 
different types of antidepressants and dementia risk11,12. A nationwide study in Denmark 
found that the rate of developing dementia was higher among persons exposed to 
antidepressants compared to those unexposed to antidepressants11. However, in a follow-up 
study, the authors reported that continued long-term treatment with older antidepressants, 
such as TCAs, was associated with a reduced rate of dementia, whereas continued treatment 
with other classes of antidepressants including SSRIs was not13. A cohort study of 
postmenopausal women aged 65 to 79 years reported that antidepressant use at baseline and 
depression severity were associated with subsequent cognitive impairment12.
In this study, we explore the association between antidepressant use and the incidence of 
dementia, using data from a longitudinal observational cohort study of elderly primary care 
patients.
2. Method
2.1.Study population
From 1991 to 1993, all patients 60 years and older attending the primary care practice in the 
Wishard Health System were approached for participation in a depression screening study. A 
total of 4,413 primary care patients were approached, of whom 115 refused; 57 were not 
able to complete the testing due to severe cognitive impairment; 284 patients were not 
eligible because they did not speak English, were in prison or a nursing home, or had a 
hearing impairment, leaving 3,957 total enrolled patients. The methods and results of the 
depression screening program have been previously reported14,15. Patients who were 
diagnosed with dementia prior to enrollment were excluded from this analysis, resulting in a 
total of 3,688 patients. The study was approved by the Institutional Review Boards of 
Indiana University-Purdue University of Indianapolis.
2.2.Data Source
Medical history information from enrollment to December 31, 2010 was extracted from the 
Regenstrief Medical Record System (RMRS)16. For this study, we retrieved dates for 
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patients’ first diagnoses (as indicated by the International Classification of Diseases, Ninth 
Revision (ICD-9) codes) contained in inpatient, outpatient and emergency room records for 
the following conditions: anemia (280 – 285), arthritis (714.,715.), atherosclerotic vascular 
disease (440.), cancer (140. –172. and 174. – 239.), cerebrovascular disease (CVD) (430. –
438.), congestive heart failure (CHF) (428., 398.91), coronary artery disease (CAD) (410., 
411., 412., 414.), chronic obstructive pulmonary disease (COPD) (491., 492., 496.), 
dementia (290.0–290.43, 291.2, 294.0–294.9, 331.0–331.9, 333.0, and 797), depression 
(296.2, 296.3, 300.4, 309.0, 309.1, 298.0, 311), diabetes (250.), hyperlipidemia, 
hypertension(401.), liver disease(570. –573.), renal disease (585.), peripheral artery disease 
(PAD) (440.2, 443.9) and thyroid disease (242., 244.) (including both hyperthyroidism and 
hypothyroidism). Demographic information including age, gender, race, years of education 
and history of smoking were collected at study enrollment. Center for Epidemiologic Studies 
Depression (CESD) score for depression and a short portable mental status questionnaire 
(SPMSQ) value for cognitive function were also collected at enrollment.
2.3.Antidepressant Use
Medication dispensing data were retrieved from the electronic medical records for any 
antidepressant dispensed including medication name, dispensing date, duration and dose 
from enrollment through December 31, 2010 or the patient’s last encounter with the health 
care system.
2.4. Study Endpoint
To avoid an immortal time bias17 due to differences in the timing of antidepressant use, each 
subject's baseline was defined as the first date a patient was prescribed an antidepressant for 
those in the medication group. Baseline was defined as the date at enrollment for patients 
who were never prescribed antidepressants. Incident dementia was identified as the first date 
that each subject was assigned a new dementia diagnosis based on ICD-9 codes. Study 
endpoint was defined as the time of diagnosis for patients with incident dementia, and the 
time of the last outpatient primary care physician (PCP) visit during follow-up for patients 
who were not diagnosed with dementia.
3. Statistical Analysis
To examine potential differential effects of SSRI and other antidepressants and also control 
for the effect of depression, we divided patients into five mutually exclusive groups. The first 
group consisted of patients who were prescribed only SSRIs throughout the follow-up period 
(Group 1: SSRIs group). The second group consisted of participants who were prescribed 
only non-SSRI antidepressants throughout the follow-up period (Group 2: non-SSRIs 
group). The third group consisted of participants who were prescribed both SSRIs as well as 
other types of antidepressants during follow-up (Group 3: mixed group). The fourth group 
included participants who were not prescribed any antidepressant during follow-up but 
whose CESD scores at enrollment were greater than or equal to 16 or who had been 
diagnosed with depression prior to enrollment (Group 4: non-users with depression). The 
fifth group consisted of participants who were not prescribed antidepressants and had no 
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significant symptoms of depression at enrollment (CESD score <16 at enrollment) (Group 5: 
non-users no depression).
Comparison of demographic characteristics and medical history among the five groups of 
participants were conducted using Chi-square tests for categorical variables and analysis of 
variance (ANOVA) for continuous variables. Cox proportional hazards models were used to 
examine whether antidepressant use was associated with dementia risk. Proportional hazard 
assumption was tested by including an interaction term with group indicator and time as 
time-dependent covariate in the Cox model. Covariates such as age or comorbid conditions 
were adjusted at individual baseline with the exception of CESD and SPMSQ which were 
measured at enrollment. Backward model selection was used to identify potential covariates 
in the Cox’s models. Since the baseline time of patients on antidepressants was after 
enrollment time, the two non-user groups had longer follow-up time than the three 
antidepressant groups. To detect the influence from the differences in follow-up times, we 
conducted three sets of Cox models using three different censoring times in our analyses 
based on the quartile survival times (50%, 75% and 100%) in the participants on 
antidepressants. The first set of models used 5-year follow-up as the censoring time which 
was the median survival time in the three antidepressants groups. The second set of models 
used 9-year censoring time and the third set of models used the entire 18 years as the follow-
up length.
We also conducted a sensitivity analysis by increasing the threshold of CESD score from 16 
to 24 in Group 4 to compare dementia risk between severely depressed non-antidepressant 
participants and antidepressant users. In a second sensitivity analysis, we included 
medication possession ratio (MPR, defined as duration on medication divided by total time) 
for patients in the antidepressants groups in order to detect a dose-response relationship. 
SAS 9.3 was used for all analyses.
4. Results
A total of 3,688 patients were included in the analysis. Mean age at enrollment was 67.9 
years (SD=7.3), with 69.1% being women. There were 14.86% patients with CESD score 
greater or equal to 16 and 5.04% with SPMSQ value greater than 4 indicating cognitive 
impairment. Median follow-up from baseline to study endpoint was 5.1 years in the cohort. 
A total of 574 (15%) participants were diagnosed with incident dementia during the entire 
observation period, of whom 231 patients were diagnosed with incident dementia during the 
first 5-year observation period, and 373 dementia events were identified during the first 9 
years of observation period.
In Table 1, we included comparisons of demographic information and medical history at 
enrollment among the five patient groups. Years from enrollment to antidepressant use, 
number of dispensing and years on antidepressants for Groups 1, 2 and 3 were also included. 
While there were many differences among the five groups, the three antidepressant user 
groups and the non-user but depressed group differed in proportions of women, African 
American participants, smokers, mean years of education, mean body mass index, and 
history of arthritis, COPD, hypertension. These four depressed groups also differed 
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significantly on mean age, mean CESD score and cognitive scores. However, the SSRIs 
group (Group 1) and the non-SSRI group (Group 2) were similar in CESD and SPMSQ 
scores. The mixed group had higher rate of diagnosed depression at enrollment as well as 
longer antidepressant use and greater number of antidepressant dispensing when compared 
to the SSRI and non-SSRI groups (Table 1).
Table 2 included results from Cox’s models with three different censoring times. In all three 
sets of models, participants who were on SSRIs (Group 1) or non-SSRIs (Group 2) during 
follow-up period had higher dementia risk than the depressed non-users (Group 4). No 
significant differences were found between mixed antidepressant users and non-users who 
were not depressed or between depressed non-users and not-depressed non-users.
When we increased the requirement for depression severity from CESD of 16 or higher to 
24 or higher in group 4, and compared each of the antidepressant user groups to the non-
users with severe depression (Table 3), we found again that SSRI users had significantly 
higher dementia risk than non-users with severe depression in all three sets of models with 
varying follow-up length (HR=2.21, p=0.01 in model 1; HR=2.19, p=0.003 in model 2; 
HR=2.26, p=0.001 in model 3). In addition, the difference between participants in the non-
SSRI group and the severely depressed non-users was marginally significant in the 9-year 
follow-up model (HR=1.54, p=0.05) and became significant in the 18-year follow-up model 
(HR=1.62, p=0.02). In sensitivity analysis of adjusting for medication possession ratio 
(MPR) in the antidepressant groups, we found that both SSRIs and non-SSRI groups had 
significantly higher dementia risk than the mixed group (5-year model HR=2.653, p=0.0053 
for the SSRIs group; HR=2.619, p=0.0017 for the non-SSRIs group). In addition, higher 
MPR was associated with higher dementia risk (HR=1.418 per 0.1 unit increase in MPR, p<.
0001) indicating a dose response relationship with dementia risk. Similar results were 
observed in the 9-year or 18-year follow-up model. We also conducted an additional 
sensitivity analysis by excluding participants with SPMSQ greater than 4 (indicating 
potential cognitive impairment) and obtained similar results.
5. Discussion
In this elderly primary care patient cohort, we found that SSRIs users were at significantly 
higher risk for incident dementia when compared to not depressed non-users and also when 
compared to non-users with depression. Patients who were taking non-SSRIs also showed 
significantly higher risk for incident dementia when compared to non-users without 
depression. Patients who took both SSRIs and non-SSRIs or who were depressed but not 
taking antidepressants showed no difference in dementia risk compared with non-users who 
were not depressed.
Few studies to date have investigated the association between antidepressant use and 
incidence of dementia. These studies report varying results depending on the types of 
antidepressants, length of treatment and the comparison group. One Danish study showed 
that the rate of dementia decreased during periods of two or more prescriptions of older 
antidepressants compared with only one prescription of older antidepressants13. In contrast, 
continued use of SSRIs or newer nonselective serotonin reuptake inhibitors was not 
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associated with decreased rate of dementia regardless of the subtype of dementia. Another 
analysis by the same group showed that people who purchased antidepressants once had an 
increased rate of dementia compared to persons unexposed to antidepressants11. A cohort 
study of postmenopausal women aged 65 to 79 years reported that antidepressant use at 
baseline, for both SSRI and TCA, and depression severity were associated with subsequent 
cognitive impairment when compared to non-depressed non-users12. When antidepressant 
users were compared to depressed non-users, the difference in risk for cognitive impairment 
was no longer significant.
One of the challenges in studying long-term outcomes in antidepressant users is untangling 
the effect of the medication from the potential effect of depression, the underlying condition 
for treatment. Previous studies have shown that late-life depression is associated with an 
increased risk for dementia, vascular dementia and Alzheimer’s disease18. Hence any 
comparisons of antidepressant users to non-depressed non-users are subject to indication 
bias as the increased dementia risk could be due to depression, not the medication. As 
randomized trial of sufficient length comparing antidepressants to non-pharmacological 
interventions in depressed and non-depressed participants is likely to pose both design 
difficulties and raise ethical considerations, analysis of large observational cohort data may 
be the only way to address this question. In our analyses, by creating different groups of 
antidepressant users and dividing the non-users into those with depression and another group 
without depression, we are able to separate the potential effects due to medication use and 
those due to both depression and antidepressant use.
It has been hypothesized previously that antidepressants may be protective of dementia. A 
recent study in 23 young healthy volunteers age 18 to 50 showed that the accumulation of 
amyloid-β (A²) in cerebrospinal fluid was slowed by 37% within hours with the treatment of 
citalopram (a SSRI) compared to placebo19. Other studies argued that antidepressants may 
have neuroprotective abilities by increasing the proliferation of neural progenitors in the 
hippocampus and prolonging the survival of these newborn neurons5,6 thus leading to 
improved cognition7. Some studies have reported the association between antidepressant use 
and increased hippocampus volume in non-geriatric subjects20–22. However, other 
neuroimaging studies have reported that antidepressant use was significantly associated with 
smaller hippocampus volume23. A recent population-based study of older adults without 
dementia showed that antidepressants use was significantly associated with smaller total 
brain, smaller hippocampal, and larger white matter hyperintensity (WMH) volume, while 
high CES-D scores were not significantly associated with any of the brain measures24. A 
common limitation of these imaging studies is that they were cross-sectional in nature, and 
most were conducted in younger participants, thus making it difficult to infer whether the 
observed association was due to prolonged depression or antidepressant use.
Other studies actually suggest that antidepressant therapy may worsen the course of 
cognitive decline in certain patients. A recent study demonstrated that treatment of 
behavioral symptoms in patients with AD with SSRI antidepressants resulted in improved 
scores on agitation rating, but worsened scores on cognitive functions25. Similarly, another 
recent study suggested that antidepressants use in patients with early stages of AD and Lewy 
body dementia (LBD) worsened cortical thinning, especially the parahippocampal regions26. 
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Thus, while much of the neurogenesis studies with antidepressants were seen in younger 
depressed subjects, quite different mechanisms may be at play in the elderly, especially 
those who are already in the prodromal stage of dementia.
The potential biological mechanism underlying the higher dementia risk in SSRI users is not 
yet clear. One animal study has demonstrated up-regulation of the GPR39 Zn2+-sensing 
receptor protein level after SSRI treatment, but not with TCA27. As it has been proposed that 
either low Zinc or excessive Zinc may lead to neurofibrillary tangles, a primary mark of 
Alzheimer’s disease and cognitive impairment28,29, a potential link between SSRI use and 
dementia may be through the zinc pathway.
A somewhat surprising finding in our results was that patients in the mixed group were not 
at increased risk of dementia despite of showing higher depression diagnosis rate, longer 
time on antidepressants and greater number of dispensing than the SSRI and non-SSRI 
groups. The use of antidepressant combination is a popular strategy in practice to treat those 
patients with treatment resistant depression30. Hence it is possible that patients in the mixed 
group were resistant to antidepressant treatment and perhaps also immune to other 
deleterious brain effects of antidepressants.
Our study has a number of strength. The cohort is relatively large with long follow-up 
period. The use of electronic medical records (EMR) eliminates recall and potential attrition 
bias. A comprehensive list of medical conditions was available from EMR so that relevant 
covariates can be included in the analysis.
Our findings may be subject to biases and artifacts that are inherent to most observational 
studies. For example, one possible explanation for the observed results may be reverse 
causation, i.e. doctors either consciously or unconsciously were more likely to prescribe 
SSRIs rather than TCA’s to older adults with cognitive impairment as there is a wide-spread 
recognition that TCAs have higher anticholinergic adverse effects31,32 and if prescribers 
were attempting to avoid these effects, they may differentially prescribe SSRIs to older 
adults with cognitive impairment. A previous study has shown that depressed patients with 
mild cognitive impairment (MCI) were more likely to develop dementia33. Although we 
excluded patients with dementia at baseline and conducted a sensitivity analysis excluding 
patients with SPMSQ scores greater than 4, it is possible that participants with non-dementia 
cognitive impairment were still included in our analysis and the co-existence of depression 
with MCI may account for the higher dementia risk. However, since we also found that the 
SSRI group had a higher dementia risk compared to the non-users with severe depression, 
the inclusion of potential MCI subjects in the analyses is unlikely to account for the results.
Another potential issue in our result is ascertainment bias, i.e. persons with depression may 
be more likely to receive an early diagnosis of dementia. However, two sub-groups of 
patients with depression, i.e. those who received mixed types of antidepressants or those not 
receiving antidepressants, were found not at higher risk of dementia, making the 
ascertainment bias an unlikely explanation for our results. Providers could have also 
mistakenly diagnosed early cognitive impairment as depression.
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The validity of using ICD-9 codes for dementia diagnosis using both inpatient and outpatient 
records was found to be high with sensitivity of 85.5 and specificity of 85.934,35. In our 
study, we used ICD-9codes contained in inpatient, outpatient and emergency room records. 
The definition for other comorbid conditions using ICD-9 codes has been used before by 
various studies with established validity36–38.
One difference in our study from previous studies is that a significant number of our subjects 
were African Americans. There are racial differences in response to antidepressant regimen, 
with African Americans generally showing significantly lower response rates than 
Caucasians39. Furthermore, depression in the elderly, especially in African Americans, is 
often associated with cerebrovascular disease which is also a major risk factor for cognitive 
decline and dementia40.
Our study also has a number of other limitations. The medical records did not include 
depression severity measures after study enrollment. Hence it is not possible for us to 
determine whether the higher dementia risk in SSRI users was due to the lack of depression 
control. Similarly, no uniform dementia severity was available in the medical record system 
to adjust for dementia severity. In addition, we do not have information on antidepressant 
use prior to participant’s enrollment. Thus it is not possible for us to separate the typical 
depression patients from patients with late-life depression. Another limitation is the use of 
dispensing data as a measure of medication exposure, which assumes that subjects 
consumed medication as prescribed. In addition, no information on the treatment indication 
for antidepressant use was available. Hence it is possible that some antidepressants 
dispensed were dispensed for non-depression indications such as pain control.
In summary, we found that SSRIs users in this elderly primary care cohort followed over 18 
years were at significantly higher risk for incident dementia when compared to not 
depressed non-users and also when compared to non-users with depression. Given the 
potential for various confounding and the limited data on depression and cognitive measures, 
our results should be considered hypothesis generating. It will be important to see whether 
our results are confirmed in other studies with more detailed information on depression and 
cognitive function. Future studies are also needed to identify potential mechanism 
underlying the observed association between SSRI use and dementia risk in the elderly 
population.
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Table 2
Cox’s PH models of time to incident dementia comparing antidepressant users with non-depressed non-
antidepressant participants.
Model 1
(5-year follow-up)
Model 2
(9-year follow-up)
Model 3
(18 year follow-up)
Parameter*, † Hazard Ratio P-value Hazard Ratio P-value Hazard Ratio P-value
Group 1:SSRIs 2.510 <.001‡ 2.303 <.001‡ 1.828 0.003‡
Group 2: Non-SSRIs 2.007 <.001‡ 1.873 <.001‡ 1.502 0.004‡
Group 3: Mixed Group 1.142 0.63 1.311 0.16* 1.082 0.63
Group 4:Depressed Non-users 0.926 0.78 0.810 0.33 0.743 0.09
Group 5: Non-depressed Non-users 1 Reference 1 Reference 1 Reference
Age at baseline 1.053 <.001 1.065 <.001 1.071 <.001
Years of education 1.053 0.04 1.017 0.38 1.001 0.93
Cerebrovascular disease 1.520 0.02 1.443 0.01 1.452 0.004
Liver disease 1.930 0.01 1.451 0.11 1.818 0.002
CESD 1.014 0.15 1.016 0.04 1.016 0.01
SPMSQ 1.450 <.001 1.368 <.001 1.307 <.001
*Covariates not significant in any of the three models were excluded.
†Covariates are adjusted at baseline except for CESD and SPMSQ which were measured at enrollment.
‡Significant difference in hazard ratio when comparing to the depressed non-user group (P<0.05)
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